Paul Nash has just been appointed as the PPI (Patient & Public Involvement) rep on the steering group of this project which aims to provide evidence as to what is the best way of treating men with newly diagnosed advanced prostate cancer. Since opening in 2005 over 10,000 participants have joined the trial. We have already reported practice-changing results that show adding docetaxel or abiraterone improve disease control and life-expectancy. Several other strategies have been tested with more results expected soon, including the results of abiraterone and enzalutamide combination and radiotherapy to the prostate in men with newly-diagnosed metastatic disease.
